.Pharmacolibrary.Drugs.ATC.J.J01GB07

Information

Netilmicin is a semisynthetic aminoglycoside antibiotic derived from sisomicin. It is used primarily for the treatment of serious infections caused by susceptible Gram-negative bacteria, such as urinary tract infections, respiratory tract infections, and sepsis. The drug has been largely replaced by other aminoglycosides or alternative antibiotics in many regions, but is still in use in some countries.

Pharmacokinetics

Pharmacokinetic parameters reported for adult patients with normal renal function after intravenous administration.

References

1. Jauregizar, N, et al., & Calvo, R (2003). Population pharmacokinetics of netilmicin in short-term prophylactic treatment. British journal of clinical pharmacology 55(6) 552–559. DOI:10.1046/j.1365-2125.2003.01783.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12814449

2. Tréluyer, JM, et al., & Pons, G (2000). Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method. Clinical pharmacology and therapeutics 67(6) 600–609. DOI:10.1067/mcp.2000.106695 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10872642

3. Sherwin, CM, et al., & Reith, DM (2008). Individualising netilmicin dosing in neonates. European journal of clinical pharmacology 64(12) 1201–1208. DOI:10.1007/s00228-008-0536-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18685839

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)